BRIEF-Amgen presents new data from phase 3 XGEVA (denosumab) study
March 03, 2017 at 16:52 PM EST
* Amgen presents new data from phase 3 XGEVA (denosumab) study in multiple myeloma patients at the 16th international myeloma workshop
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|